Compare OGN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | NNNN |
|---|---|---|
| Founded | 1923 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2020 | N/A |
| Metric | OGN | NNNN |
|---|---|---|
| Price | $5.85 | $23.92 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.75 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 26.3K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | ★ $8.42 | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.76 | $5.91 |
| 52 Week High | $14.94 | $55.65 |
| Indicator | OGN | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 25.56 | 52.80 |
| Support Level | N/A | $19.53 |
| Resistance Level | $7.87 | $30.70 |
| Average True Range (ATR) | 0.22 | 1.97 |
| MACD | 0.00 | 0.41 |
| Stochastic Oscillator | 10.00 | 84.48 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.